Monday, November 29, 2010
Location: Brussels, Belgium
Minutes Meeting Geneva, May 2010
In May this year the IVTIP members were given the opportunity to elect a new Board for the period 2010-2012.
This Board was installed, and will have its first meeting on July 1st.
The members are:
Annemarie de Heer (Secretariat)
Bart de Wever
(Altexa / IVTIP Executive Officer)
Horst Fuchs (CellSystems)
Marianna Gaca (BAT)
Cyrille Krul (TNO)
Stan Mikulowski (LinkMed/Biovator)
Albrecht Poth (Harlan)
Erwin L. Roggen (Novozymes/IVTIP President)
Maya Vila (Advancell)
This part of the website is for IVTIP members and observers only.
Access is only possible with a username and password, provided by the
IVTIP Secretariat.
of European companies with a genuine and active interest in in vitro testing (replacement) to be used in regulatory/safety testing or for early decision-making in compound discovery and development. IVTIP endorses the National Research Council’s ‘Toxicity Testing in the 21st Century’ strategy as the ultimate fundamental replacement of animal experimentation for regulatory/safety testing.
IVTIP is also supportive of applying opportunities resulting in the reduction of the number of animals and/or allowing for refinement of existing animal experiments. Thus, it is fair to say that IVTIP actively contributes to the promotion of dissemination of progress and knowledge, and transfer of state-of-the-art technologies related to the 3Rs:replacing, reducing and refining animal testing. In addition, IVTIP actively endorses a 4th R: responsibility towards animals as well as towards the growing demand by society for better ways of assuring safety.
on (i) the implementation of the 4Rs principle by industry, and (ii) the acceptance of the emerging alternative methods by the regulatory authorities. By seeking close contacts with the European Commission (EC) and the European Partnership for Alternatives to Animal Testing (EPAA), IVTIP focuses on Europe, but it also keeps an open eye on global research activities and industrial needs, realizing that a global approach is required for getting acceptance of the emerging testing methods.
Companies fitting the profile (a genuine and active interest in in vitro testing, either in research or in applications) may apply for membership, mentioning their activities in in-vitro testing, what they think IVTIP can do for them and what they think they can contribute to IVTIP. The application is considered by the IVTIP Board of Directors. Small and medium-sized companies (SMEs) are particularly encouraged to apply for membership.
The annual membership fee is 825 EURO for small enterprises, 1,650 EURO for medium-sized enterprises and 3,300 EURO for large enterprises. Criteria regarding size are available from the IVTIP secretariat